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ABSTRACT
Objectives: Treatment of endometriosis prior to IVF/ICSI could be followed by the significant reduction of ovarian reserve. 
The aim is to identify potential markers of the IVF/ICSI outcome in patients with endometriosis associated infertility and 
to evaluate their clinical significance.
Material and methods: The prospective cohort study included 73 patients with primary infertility caused by endometriosis 
that were subjected to 77 IVF/ICSI cycles. Patients were classified into two groups. In the first group some type of treatment 
had previously been applied, and in the second group patients were immediately subjected to the IVF/ICSI procedures. 
Results: When pregnancy was achieved, there were significantly more patients under 35 years of age, more patients 
with primary infertility duration up to 3 years, and more patients with endometriosis that was previously treated (77.4%) 
(p < 0.039). In the cases of the successful outcome Endometriosis Fertility Index > 7, lower basal FSH and FSH/LH ratio were 
found, as well as significantly higher basal E2, basal P4 and AMH. Significantly lower doses of gonadotropins were needed 
in cases of the successful outcome, and long protocol with agonists was more frequently used. Multivariate logistic regres-
sion analysis showed that previous therapy of endometriosis, P4 ≥ 0.7 ng/mL, AMH ≥ 0.9 ng/mL, A class of embryos, and 
the use of long protocol with agonists were predictors of the successful IVF/ICSI outcome. 
Conclusions: Therapy for endometriosis, AMH and P4 levels appeared to be predictors for the successful IVF/ICSI outcome 
and the use of long protocol with agonists could be advised in these cycles.
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INTRODUCTION
The link between endometriosis and infertility is usually 
explained by the simultaneous effect of multiple mecha-
nisms, such as immune factors, disturbed folliculogenesis 
and ovulation, oocyte degeneration and apoptosis, com-
promised fertilization and abnormal embryogenesis [1–3]. 
Surgical treatment of endometriosis prior to IVF is common, 
but could be followed by the significant reduction of ova-
rian reserve which has a negative impact on fertility [4, 5].
Many studies suggest that women with endometriosis 
have lower ovarian reserve and higher basal FSH level than wo-
men of the same age who do not have endometriosis [6]. 
Serum anti-Müllerian hormone (AMH) level accurately re-
flects the ovarian reserve, which may be lower in women 
with endometriosis, and can predict the ovarian response to 
controlled ovarian hyperstimulation (COH) in these patients 
[7, 8]. Endometriosis fertility index or EFI was proposed for 
the fertility assessment after endometriosis treatment [9]. 
This index includes anamnestic parameters such as age, 
duration of infertility, parity, as well as anatomical and func-
tional assessment of the disease severity. 
The aim was to identify potential markers of the success-
ful IVF/ICSI outcome in patients with endometriosis asso-
ciated infertility and to evaluate their clinical significance. 
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MATERIAL AND METHODS
Patients
The prospective cohort study was conducted at the 
tertiary institution for a period of 5 years, and included 73 pa-
tients with primary infertility caused by endometriosis that 
were subjected to 77 IVF/ICSI cycles. The study was approved 
by the Ethics committee of the Medical faculty University of 
Belgrade, Serbia, and all patients gave informative consent. 
Inclusion criteria were: age up to 40 years, primary infertility 
lasting for more than a year and caused by endometriosis, 
the absence of associated infertility factors, body mass in-
dex (BMI) less than 30 kg/m2, regular cycles 24–35 days, or 
previously diagnosed endometriosis independently to infer-
tility treatment. Patients were classified into two groups. In 
the first group (Group I) some kind of endometriosis treat-
ment had previously been applied before the introduction 
to the IVF/ICSI, and in the second group (Group II) patients 
were immediately subjected to the IVF/ICSI procedures. The 
Group I consisted of patients diagnosed with endometriosis 
on surgical treatment that could have been followed by the 
medical treatment. Therefore in the study group we formed 
two subgroups of patients, first subgroup (A) with combi-
ned surgical and medical treatment and second subgroup 
of patients (B) who were only surgicaly treated. The Group 
II consisted of patients with endometriosis that were not 
treated and those patients were immediately introduced 
to the IVF/ICSI. In these cases endometriosis was diagnosed 
previously and independently to infertilty treatment or pre-
sence of endometrioma was confirmed on ultrasound. Age, 
body mass index (BMI), endometriosis fertility index (EFI), 
endometrioma presence, diameter and laterality, as well as 
the ASRM stage were determined for all patients. 
Therapy 
Surgical treatment was applied in patients with symp-
toms such as pelvic pain and dysmenorrhoea, and/or with 
severe forms of endometriosis or presence of endome-
trioma > 3 cm, or bilateral endometriomas > 3 cm. Surgi-
cal treatment involved laparoscopic approach, excision of 
the endometriotic capsule with stripping technique and 
achieving hemostasis using bipolar forceps. Depending 
on the disease severity, excision and vaporization of other 
endometriotic foci were made as well. 
Combined surgical and medicament treatment invo-
lved the introduction of gonadotropin-releasing hormone 
(GnRH) agonists every 28 days for 3–6 months immediately 
after the surgical treatment and the histopathological verifi-
cation of the endometriosis. Additional medical therapy was 
introduced if the patients had more pronounced symptoms 
before surgery, and/or had more severe form of endome-
triosis with dissemination that was verified on operation. 
In the Group II presence of endometriomas was confir-
med on transvaginal ultrasonographic examination, or en-
dometriosis was found on laparoscopy during the infertility 
evaluation, but without surgical treatment, or endometriosis 
was previously diagnosed independently to infertility eva-
luation and was without treatment. Ultrasound diagnosis 
of endometriomas up to 3 cm as a round homogenous 
hypoechoic formation in the ovarian tissue, presence of less 
severe endometriosis with endometriotic focci in the pelvis, 
on uterus, uterine ligaments and ovaries and without tubal 
factor on diagnostic laparoscopy were the selection criteria 
for the Group II. Those patients were directly introduced to 
the IVF/ICSI.  
EFI score was determined for all patients. If the total 
score is greater than 7, higher is the probability for sponta-
neous pregnancy. In this study EFI was used for the success 
assessment of the IVF/ICSI cycles. 
Endocrinological status
On the third day of the menstrual cycle, before COH, 
levels of follicle-stimulating hormone (FSH), luteinizing 
hormone (LH), estradiol (E2) and progesterone (P4) were 
determined for all patients. AMH was determined for all 
patients independently to menstrual cycle. For the previo-
usly treated patients AMH was determined one month after 
surgery and prior to the additional medical treatment. For 
the patients without previous treatment of endometrio-
sis AMH was determined prior to IVF/ICSI. FSH (IU/l), LH 
(IU/L), E2 (pg/mL), Pg (ng/mL) values were determined by 
the chemiluminescent immunoassay (ECLIA, Access 2 im-
munoassay system, Beckman Coulter). FSH/LH ratio was 
determined for each patient. Serum AMH (ng/mL) values 
were determined by the enzyme-linked immunosorbent 
assay (ELISA, AMH II, Beckman Coulter) and were defined 
in interval ranges as low (< 1 ng/mL), normal (1–5 ng/mL), 
and high (> 5 ng/mL). 
IVF/ICSI procedure
COH was performed according to three protocols: long 
protocol with GnRH agonist, short protocol with GnRH ago-
nist and short protocol with GnRH antagonist. 
The long protocol implied pituitary suppression with Di-
phereline®, (Ferring Pharmaceuticals) at a dose of 0.1 mg per 
day, for 7 days before the onset of the cycle and continued 
daily to the end of stimulation of ovulation. Short protocol 
implied pituitary suppression with GnRH agonist, tryptorelin 
at a dose of 0.1 mg per day starting from the 2nd or 3rd day 
of the cycle, daily to the end of stimulation of ovulation. 
Short protocol with the GnRH antagonist implied the use 
of the use of GnRH antagonist cetrorelix (Cetrotide®, Merck 
Serono) at a dose of 0.25 mg per day from the sixth day 
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of stimulation and continued daily to the end of stimula-
tion. Ovarian stimulation started on day 2. or 3. of the cycle 
and was conducted with daily subcutaneus injections of 
FSH (follitropin α — Gonal F®, Merck Serono or follitropin β 
— Puregon®, MSD) and/or HMG (menotropin — Menopur®, 
Ferring Pharmaceuticals) with starting dose of 225 I.U. The 
ovarian stimulation was monitored by determining serum 
E2 and LH levels, as well as transvaginal ultrasonographic 
monitoring of follicular growth and endometrium thickness 
every second day from the day 6 of the cycle. When E2 values 
were above 400 pg/mL and there were at least two follicles 
greater than 18 mm, choriogonadine was administered at 
a dose of 5000 to 10,000 IU. Follicular and oocyte aspiration 
was performed by transvaginal ultrasound control 34 to 
36 hours after the administration of HCG. Selection of the 
protocols depended on the age, EFI, AMH as well as AFC, 
FSH and E2 levels.
 Ovarian response to stimulation was evaluated accor-
ding to the number of retrieved oocytes, as poor (≤ 4 oocy-
tes), adequate (5–15 oocytes) and excessive (> 15 oocytes). 
Total number of embryos and their quality was assesed by 
embryologists and four classes of embryos were defined 
A, B, C and D, where A class represents the highest quality 
of embryos.
Data collection
Age, BMI, EFI, endometrioma presence, diameter and 
laterality, as well as the ASRM stage were determined for 
all patients in the defined groups prior to the IVF/ICSI tre-
atment. Patients from the Group I were introduced to the 
IVF/ICSI after the endometriosis treatment, while patients 
from the Group II were directly introduced to the IVF/ICSI. 
The cycle outcomes were followed up, and afterwards 
cycles were analyzed depending on the outcome. Age, in-
fertility duration, BMI, EFI, ASRM stage and score, hormone 
levels, the use of protocols for COH, ovarian response and 
embryos were analysed in relation to the IVF/ICSI cycles 
outcome.
Statistical analysis 
Descriptive statistics were used to summarize demogra-
phic, biochemical and clinical characteristics. Categorical 
variables were compared using Chi-square test. Continuous 
variables were compared by using ANOVA-test, or Kruskal-
-Wallis test. The association of selected variables with outco-
me was assessed with the Binary logistic regression analyses 
and determined the significance of the predictors. A signifi-
cance of 0.05 was required for a variable to be included into 
the multivariate logistic regression model — Backward wild 
method, whereas 0.1 was the cut off value for exclusion. 
Odd ratios with the corresponding 95% confidence intervals 
were estimated. Analyses were performed using SPSS for 
Windows version 22 (SPSS, Inc, Chicago, IL).
RESULTS
Patients
The study included 73 patients who underwent 77 cycles 
of IVF/ICSI. The average patient’s age was 34.14 ± 3.53 years, 
and average BMI was 22.55 ± 2.45. BMI lower than 25 had 
64 (87.7%) patients. 
In the Group I there were 46 (63%) patients, while in the 
Group II were 27 (37%) patients. In the Group I 25 (54.3%) 
patients had surgical treatment that was followed by the 
medical treatment, and 21 (45.7%) patients were only sur-
gically treated. 
The description of the patients in the groups, prior to 
introduction into the IVF/ICSI procedures is shown in Ta-
ble 1. The groups did not differ in any of the tested variables, 
except in the size of the endometriotic cyst, ASRM stage 
and the ASRM score of endometriosis. Significantly larger 
endometriomas (p ≤ 0.01) and higher ASRM scores (p < 0.01) 
were found in the subgroup of patients with combined (both 
surgical and medical) treatment compared to the subgroup 
of only surgically treated patients. 
Outcomes
Description of all IVF/ICSI cycles in relation to the out-
come is shown in Table 2. In cycles with positive outcome 
(pregnancy), there were significantly more patients under 
35 years (71%) (p < 0.044), infertility duration up to 3 years 
(67.7%) (p < 0.023), and with endometriosis that was previo-
usly treated (77.4%) (p < 0.039). EFI > 7 was more frequent in 
the cases of pregnancy (p < 0.007). In these cases significan-
tly lower basal FSH (p < 0.007), FSH/LH ratio (p < 0.002) were 
found, as well as significantly higher basal E2 (p < 0.003), 
basal P4 (p < 0.001) and AMH (p < 0.000). Significantly lower 
doses of gonadotropins were needed in the cycles with 
achieved pregnancy (p < 0.028) (Tab. 2). The probability of 
success with long protocol with agonists was almost 3 times 
higher compared to the short protocols (OR = 2.98, 95% CI 
1.123 to 7.93). Adequate ovarian response (58.1%) was sta-
tistically significant (p < 0.008), more quality embryos were 
obtained (90.3%) (p < 0.001) and more clinical pregnancies 
(77.4%) were achieved (p < 0.0001) in the group of cycles 
with positive outcome (Tab. 2).
Pregnancy rate per embriotransfer (PR/ET) was signifi-
cantly higher in the Group I (44.19%) compared to the Group 
II (21.74%), (p < 0.05). Subgroup A with combined therapy 
(both surgical and medical) had higher PR/ET (47.83%) com-
pared to the Group II (21.74%), (p < 0.05). Subgroup B (only 
surgical treatment) showed non-significantly elevated PR/ET 
(40.0%) compared to the Group II. 
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ROC analysis
The results of the FSH/LH ratio ROC analysis was 
AUC = 0.711, with a 95  % confidence interval CI 95% 
0.594–0.828, p < 0.002 (Fig. 1). The FSH/LH ratio cut-off 
point of 1.99 was determined with sensitivity of 68%, and 
specificity of 61%. 
The results of the AMH ROC analysis was AUC = 0.795, 
with a 95  % confidence interval CI 95% 0.683–0.907, 
p < 0.0001 (Fig. 2). The AMH cut-off point of 0.89 was de-
termined with sensitivity of 81%, and specificity of 50%. 
Successful IVF/ICSI outcomes were more frequent when: 
FSH < 7 IU/l (74.2%, p < 0.001), FSH/LH < 2 (67.7%, p < 0.023), 
Table 1. Description of the IVF/ICSI patients in relation to the endometriosis therapy
x ± SD
Group I Group II
p signif.
Median x ± SD Median
Age (years) 33.88 ± 3.20 34 34.43 ± 3.95 36 ‡ 0.507/ns
BMI [kg/m2] 22.66 ± 2.44 22.6 22.66 ± 2.58 22.7 ‡ 0.996/ns
EFI 6.04 ± 1.96 6 5.86 ± 1.63 6 ‡ 0.676/ns
FSH [IU/l] 7.43 ± 3.78 7.3 6.81 ± 3.24 6.55 † 0.505/ns
LH [IU/l] 3.99 ± 2.37 3.7 3.45 ± 2.29 3.3 † 0.312/ns
FSH/LH 2.32 ± 1.41 1.89 2.46 ± 1.26 2.06 † 0.525/ns
E2 [pg/mL] 41.75 ± 21.13 35 49.42 ± 41.39 35 † 0.958/ns
P4 [ng/mL] 1.05 ± 0.92 0.7 1.02 ± 1.33 0.56 † 0.325/ns
AMH ([ng/mL] 1.36 ± 1.12 0.9 1.54 ± 1.15 1.17 † 0.164/ns
Cyst size [mm] 56.5 ± 13.54 59 25.3 ± 6.04 22 ‡ 0.0001***
Group I 
N = 49 [%]
Group II
N = 28 [%] p signif.
EFI interval
≤ 7 31 (63.3) 22 (78.6)
*0.163/ns
> 7 18 (36.7) 6 (21.4)
Laterality
Without cyst 2 (4.1) 22 (78.6)
*0.0001***Unilateral cyst 36 (73.5) 2 (7.1)
Bilateral cysts 11 (22.4) 4 (14.3)
ASRM stage
ASRM I/II 4 (8.20) 13 (46.4)
*0.002**
ASRM III/IV 45 (91.8) 15 (53.6)
ASRM score
< 16 4 (8.20) 13 (46.4)
*0.001***
16–40 25 (51.0) 12 (42.9)
41–70 14 (28.6) 2 (7.1)
71 + 6 (12.2) 1 (3.6)
(x ± SD) — mean value ± standard deviation, median, * — Chi square — χ2 test, ‡ — F test, † — Kruskal Wallis test, ns — p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001
FSH/LH
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Figure 1. FSH/LH ratio in relation to the outcome
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Figure 2. AMH in relation to the outcome
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E2 ≥ 30 pg/mL (77.4%, p < 0.009), P4 ≥ 0.7 ng/mL (71.0%, 
p < 0.0001), AMH ≥ 0.9 ng/mL (80.6%, p < 0.006) (Tab. 3).
Univariate and multivariate logistic regression 
analysis
Table 4 represents univariate and multivariate logi-
stic regression model for the outcomes. Predictors of the 
successful IVF/ICSI outcome in multivariate logistic regres-
sion model were: A class of embryos (OR = 41.749, 95% 
CI 41.749–383.61), AMH ≥ 0.9 ng/mL (OR = 22.74, 95% CI 
1. 2.176–237.68), P4 ≥ 0.7 ng/mL (OR = 6.429, 95% CI 1.195–
–34.593), previous therapy of endometriosis (OR = 5.241, 
95% CI 1.598–17.193), and the use of the long protocol with 
agonists (OR = 5.796, 95% CI 1.007–33.349).
DISCUSSION
Pregnancies following IVF/ICSI were mostly achieved 
in patients under 35 years with infertility duration up to 
3 years. EFI score associated anamnestic and clinical data 
very well and has proven to be a good predictor of the 
Table 2. Description of the IVF/ICSI cycles in relation to the outcome
Total
[%]
Pregnancy No pregnancy
P sgn.
No [%] No [%]
Therapy of 
endometriosis
Therapy group 49 (63.6) 24 (77.4) 25 (54.3)
*0.039*
ART group 28 (36.4) 7 (22.6) 21 (45.7)
Age (x ± SD) 34.08 ± 3.47 33.1 ± 3.35 34.74 ± 3.43 ‡ 0.041*
Age ≤ 35 years 44 (57.1) 22 (71.0) 22 (47.8) *0.044*
Infertility ≤ 3 years 40 (51.9) 21 (67.7) 19 (41.3) *0.023*
BMI (x ± SD) 22.66 ± 2.48 22.83 ± 2.46 22.55 ± 2.51 ‡ 0.629/ns
BMI ≤ 25 65 (84.4) 26 (83.9) 39 (84.8) *0.914/ns
EFI > 7 24 (31.2) 15 (48.4) 9 (19.6) *0.007
ASRM
ASRM I/II 17 (22.1) 6 (19.4) 11 (23.9)
*0.636/ns
ASRM III/IV 60 (77.9) 25 (80.6) 35 (76.1)
Basal FSH [IU/l] (x ± SD) (M) 7.20 ± 3.59 (6.9) 6.04 ± 3.2 (5.6) 7.99 ± 3.65 (8.0) † 0.003**
Basal LH  [IU/l] (x ± SD) (M) 3.8 ± 2.34 (3.7) 4.24 ± 2.71 (3.7) 3.5 ± 2.04 (3.55) † 0.361/ns
FSH/LH ratio (x ± SD) (M) 2.37 ± 1.35 (1.98) 1.79 ± 0.92 (1.79) 2.76 ± 1.46 (2.25) † 0.002**
Basal E2 [pg/mL] (x ± SD) (M) 44.54 ± 30.07 (35) 54.71 ± 31.77 (45) 37.69 ± 27.12 (29) † 0.001**
Basal P4 [ng/mL] (x ± SD) (M) 1.04 ± 1.08 (0.67) 1.59 ± 1.39 (1.08) 0.66 ± 0.57 (0.50) † 0.0001**
AMH [ng/mL] (x ± SD) (M) 1.42 ± 1.12 (0.96) 2.24 ± 1.32 (2.34) 0.88 ± 0.45 (0.90) † 0.0001***
Gonadotropin [IU] (x ± SD) (M) 2332.79 ± 791.63M = 2100
2092.74 ± 725.18
M = 2025
2494.57 ± 800.85
M = 2250 ‡ 0.028*
Protocol
Long and agonists 26 (33.8) 15 (48.4) 11 (23.9)
*0.026*Short (agonists or 
antagonists) 51 (66.2) 16 (51.6) 20 (76.1)
Gonado tropins
rFSH 31 (40.3) 15 (55.6) 16 (32.0)
*0.095/nsHMG 12 (15.6) 2 (7.4) 10 (20.0)
rFSH+HMG 34 (44.2) 10 (37.0) 24 (48.0)
Ovarian response
Poor 34 (44.2) 8 (25.8) 26 (56.5)
*0.008***Adequate 37 (48.1) 18 (58.1) 19 (41.3)
Excessive 6 (7.8) 5 (16.1) 1 (2.2)
Embryo class
No embryos 11 (14.3) 0 (0.0) 11 (23.9)
*0.001***Adequate (A+B) 52 (67.5) 28 (90.3) 24 (52.2)
Inadequate (C+D) 14 (18.2) 3 (9.7) 11 (23.9)
Pregnancy
Clinical 24 (31.2) 24 (77.4) 0 (0.0)
*0.0001***Biochemical 7 (9.1) 7 (22.6) 0 (0.0)
No pregnancy 46 (59.7) 0 (0.0) 46 (100.0)
(x ± SD) — mean value ± standard deviation, (M) — median, * — χ2 test, ‡ — F test, † — K-W test, ns — p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001
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successful treatment. It is well known that superior variable 
in clinical pregnancy prediction is the patient’s age, but 
several hormones can predict oocyte count in different 
age groups as well [10]. FSH is increasing, while AMH is 
decreasing with age, and some studies point out that AMH 
is a more reliable biomarker compared to FSH [11]. The AMH 
level well correlates with other markers of ovarian reserve, 
such as antral follicle count (AFC) or day 3 serum FSH, and 
can predict ovarian responsiveness to COH [12]. It is widely 
quoted that AMH has equal sensitivity and specificity as 
AFC, and is better than FSH, E2, LH, FSH/LH ratio or inhibin-
-B levels [13].
Pregnancies were achieved in all ASRM stages of en-
dometriosis equally. Higher stages of endometriosis had 
previously determined the therapy selection, thus endo-
metriosis as a chronic disease was suppressed and micro 
Table 3. Applied Cut-off values of hormones in relation to the outcome
Total [%]
No [%]
Pregnancy No pregnancy P sign
χ2testNo [%] No [%]
FSH
< 7 IU/l 39 (50.6) 23 (74.2) 16 (34.8)
0.001***
≥ 7 IU/l 38 (49.4) 8 (25.8) 30 (65.2)
FSH/LH
< 3 60 (77.9) 28 (90.3) 32 (69.6)
0.031*
≥ 3 17 (22.1) 3 (9.7) 14 (30.4)
FSH/LH
< 2 40 (51.9) 21 (67.7) 19 (41.3)
0.023*
≥ 2 37 (48.1) 10 (32.3) 27 (58.7)
E2
< 30 pg/mL 31 (40.3) 7 (22.6) 24 (52.2)
0.009**
≥ 30 pg/mL 46 (59.7) 24 (77.4) 22 (47.8)
P4
< 0.7 ng/mL 42 (54.6) 9 (29.0) 33 (71.7)
0.0001**
≥ 0.7 ng/mL 35 (45.4) 22 (71.0) 13 (28.3)
AMH
< 0.9 ng/mL 29 (37.7) 6 (19.4) 23 (50.0)
0.006**
≥ 0.9 ng/mL 48 (62.3) 25 (80.6) 23 (50.0)
χ2 test, ns — p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001
Table 4. Binary logistic regression analysis (LRA) for the outcomes 
 
Univariate LRA Multivariate LRA
OR Sig.
95% C.I.
OR Sig.
95% C.I.
Lower Upper Lower Upper
Therapy 1.697 0.043 1.018 2.830 5.241 0.006 1.598 17.193
Age ≤ 35 2.667 0.047 1.013 7.017        
Primary infertility ≤ 3 2.984 0.025 1.149 7.753        
EFI > 7 3.854 0.009 1.399 10.617        
Endometrioma presence 2.679 0.071 0.919 7.808        
FSH/LH < 2 2.984 0.025 1.151 7.753        
E2 ≥ 30 pg/mL 3.740 0.011 1.347 10.388        
P4 ≥ 0.7 ng/mL 6.205 0.0001 2.268 16.980 6.429 0.030 1.195 34.593
AMH ≥ 0.9 ng/mL 4.167 0.008 1.441 12.051 22.740 0.009 2.176 237.68
Aspirated oocytes > 5 3.582 0.009 1.369 9.375        
Adequate/excessive ovarian response 3.737 0.003 1.384 10.094
Obtained embryos > 2 3.272 0.014 1.266 8.460        
A class of embryos 6.429 0.0001 2.277 18.147 41.749 0.001 4.544 383.61
B class of embryos 3.136 0.024 1.164 8.448
Long protocol 2.983 0.023 1.123 7.927 5.796 0.049 1.007 33.349
Gonadotropins doses < 2000 IU 2.656 0.047 1.013 6.965
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conditions for achieving pregnancy were established. We 
found that PR/ET was significantly higher in the Group I com-
pared to the Group II, as well as that PR/ET was higher in 
the Subgroup A compared to the Group II. This suggests 
that previous endometriosis therapy had positive influence 
on the IVF/ICSI outcome, especially in the cases of seve-
re endometriosis that had been treated with combined, 
both surgical and medical therapy. In multivariate logistic 
regression the therapy for endometriosis was found to be 
a predictive factor for pregnancy after IVF/ICSI.
Studies report that endometriosis presence does not 
affect ovarian response to exogenous gonadotropin sti-
mulation when the ovarian reserve is not significantly im-
paired  [14]. Ovarian reserve could be compromised after 
previous endometriosis surgical treatment. In our study it 
might be that additional medical therapy preserved ova-
rian reserve and at the same time suppressed pathophysio-
logical pathways that affect oocyte maturation, fertilization 
and implantation. 
Even though FSH, as mostly used ovarian marker could 
be normal, some patients might respond poorly to COH [15]. 
Elevated FSH/LH ratio ≥ 2 is strongly related to the reduced 
ovarian response to stimulation and lower pregnancy rates 
in IVF treatment [16]. In the cases of achieved pregnancy, 
we found significantly lower basal FSH, FSH/LH ratio, as 
well as significantly higher basal E2, basal P4 and AMH with 
less gonadotropins spent than in cases with no pregnancy. 
Yoo et al. showed that serum AMH level in women with 
endometriosis had a positive correlation with the number 
of retrieved oocytes and the mature oocytes, while there 
was no correlation between serum FSH and number of ma-
ture oocytes, suggesting that AMH level might be a better 
marker than serum FSH or age for predicting the number 
of retrieved oocytes [6]. Similar findings were found in our 
study as well. Bilaterality of the endometriomas also repre-
sents a significant factor for AMH decline after surgery [17]. 
The presence of endometrioma does not reduce the 
number of retrieved oocytes in a COH cycle for IVF, but the 
ovarian response could be affected by the size of endo-
metriomas, bilaterality, previous surgeries, recurrence, and 
the patient’s age [18]. Also there are studies suggesting 
that patients age and cyst diameter were not related to 
the extent of AMH decline, while the excision of bilateral 
endometriomas might be associated with a greater loss of 
ovarian reserve [13, 19]. In addition levels of AMH declined 
more in patients with endometriomas than in patients with 
other benign ovarian cysts [13]. In women with endome-
triosis, the ORs of having AMH levels less than 1 ng/mL are 
significantly increased both in advanced age and in the 
cases of a previous surgery as well, making it independent 
factor for diminishing ovarian reserve [20]. Ovarian reserve 
damage due to surgical treatment of endometriomas further 
requires significantly higher gonadotrophins doses, longer 
ovarian stimulation and usually has higher cancelation rate 
for poor response [21]. However, after the prolonged down-
-regulation with GnRH agonists following the operation, 
every 4 weeks for 3 months, size of the growing follicles 
appears to be normal, which is indicated by normal AMH 
levels 4 and 8 weeks after the therapy [22]. It could be recom-
mended that when the lower ovarian response is expected, 
AMH serum level should be measured previous to a COH to 
optimise the dosage of gonadotropin treatment.
Decreased ovarian response and lower pregnancy ra-
tes, as well as higher cycle cancellation rate are expected 
when FSH/LH ratio is elevated in the presence of a normal 
basal FSH [23]. Poor IVF outcomes even with FSH/LH ra-
tios ≥ 2 were found, despite the use of aggressive protocols 
and higher doses of ovarian stimulation drugs [24]. FSH/LH 
ratio is mostly correlated with the lower LH level and has 
only a small correlation with the FSH level [24]. 
Higher concentrations of peritoneal fluid in patients 
with minimal/mild endometriosis may contain factors that 
compromise ovarian steroidogenesis and reduce P4 release 
[25]. Low progesterone may alter fine balance between me-
talloproteinases and tissue inhibitors, thus demanding its 
supplementation in women with endometriosis undergoing 
IVF [26]. As recent studies have shown, in endometriosis we 
can expect higher concentration of progesterone (PR) and 
estrogen receptors (ER) on granulosa cells [27]. When the 
endometriosis is treated, expression of the PR on granulosa 
cells might be lower, thus serum P4 levels may be higher 
compared to those with non-treated endometriosis. Higher 
expression of PR on granulosa cell may lead to inadequate 
follicular maturation, obtaining low quality oocytes and em-
bryos. Quality embryos can be retrieved from granulosa cells 
with lower PR expression, so the reduction of PR stimulated 
by LH might regulate oocyte maturity [27].
The small number of retrieved oocytes, mature oocytes, 
and lower pregnancy rates were found in cases with increased 
FSH/LH ratio ≥ 2, when GnRH antagonists were administered 
[28]. Long protocol with agonists was most frequently used 
protocol in the cycles with achieved pregnancy. Studies show 
that GnRH-agonist protocol may result in higher pregnancy 
as well as live-birth rates after fresh ET in women with endo-
metriosis [29]. It is possible that protocols with antagonists 
might negatively impact endometrial receptivity in these 
situations [29]. The role of LH supplementation for impro-
ving outcomes in patients undergoing COH for IVF cycles is 
unclear, although it has been suggested that patients with 
poor ovarian reserve may benefit from LH supplementation 
[30]. In our study significantly higher AMH in the cycles with 
achieved pregnancy shows adequate ovarian reserve. More 
gonadotropins were used in the Group II in the cycles with 
reduced ovarian reserve that were followed by unsuccessful 
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outcomes. In this group we frequently more used rFSH and 
HMG, which is the most common choice in the situations 
where a worse ovarian response is expected. The use of HMG 
in patients with high basal FSH/LH, may be associated with 
significantly higher number of top-quality embryos, higher 
implantation and clinical pregnancy rates when compared 
with the use of rFSH [31]. In the pregnancy achieved cycles 
we used rFSH in 55.6%, and the combination of FSH and HMG 
in 37% of cycles. We found no difference between the use of 
rFSH and HMG between the groups. Additional treatment 
with GnRH agonist before IVF-ET or ultralong GnRHa therapy 
has been reported to improve the outcome of IVF/ET in endo-
metriosis, possibly due to reduction of the detrimental effects 
of cytotoxic cytokines and oxidative stress in the ovary in 
these patients [32]. Hence, it might be suggested to continue 
to IVF/ICSI procedures immediately after the endometriosis 
treatment especially if the GnRH agonists are used.
Ballester M. in his study pointed up that covariates 
such as patients age, serum AMH level, presence of DIE and 
number of IVF/ICSI cycles were clinically significant in the 
pregnancy rate prediction after IVF/ICSI cycles in patients 
with endometriosis [33]. Patients with serum AMH levels of 
0.6 ng/mL or above had twice the number of oocytes retrie-
ved, a greater number of day 3 embryos and a higher clinical 
pregnancy rate compared with patients with lower AMH 
levels [33]. In the multivariate logistic regression analysis we 
found that predictors for the successful IVF/ICSI outcome 
were: previous therapy for endometriosis, AMH ≥ 0.9 ng/mL, 
P4 ≥ 0.7 ng/mL, the use of the long protocol with agonists, 
and the A class of embryos.
CONCLUSIONS
Endometriosis should be treated before attempting 
IVF/ICSI either surgically or with medical therapy. Special 
care must be taken over preserving ovarian reserve, whose 
superior marker is AMH. Preserved ovarian reserve is the 
basis of good response to stimulation, and the use of long 
protocol with agonists could be advised.
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